The Novel DNA Binding Mechanism of Ridinilazole, a Precision <i>Clostridiodes difficile</i> Antibiotic-Reference-Cited by-同舟云学术

The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic

Published:2023-05-17 Issue:5 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Mason Clive S.¹^ORCID,Avis Tim¹,Hu Chenlin²,Nagalingam Nabeetha¹,Mudaliar Manikhandan¹,Coward Chris¹,Begum Khurshida²,Gajewski Kathleen³,Alam M. Jahangir²,Bassères Eugenie²,Moss Stephen⁴,Reich Stefanie⁴,Duperchy Esther⁵,Fox Keith R.⁶,Garey Kevin W.²,Powell David J.⁵

Affiliation:

1. Summit Therapeutics, Cambridge, United Kingdom

2. Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA

3. Department of Biology & Biochemistry, University of Houston Colleges of Natural Sciences and Mathematics, Houston, Texas, USA

4. Domainex Ltd., Cambridge, United Kingdom

5. Summit Therapeutics, Abingdon, United Kingdom

6. School of Biological Sciences, University of Southampton, Southampton, United Kingdom

Abstract

Clostridioides difficile infection (CDI) causes substantial morbidity and mortality worldwide with limited antibiotic treatment options. Ridinilazole is a precision bisbenzimidazole antibiotic being developed to treat CDI and reduce unacceptably high rates of infection recurrence in patients.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01563-22

Reference41 articles.

1. CDC. 2019. Antibiotic resistance threats in the United States 2019. CDC Atlanta GA.

2. Treatment of Clostridium difficile-associated disease: old therapies and new strategies

3. Can we identify patients at high risk of recurrent Clostridium difficile infection?

4. Recurrent Clostridium difficile infection is associated with increased mortality

5. Risk of complications and mortality following recurrent and non-recurrent Clostridioides difficile infection: a retrospective observational database study in England